Semaglutide vs Tirzepatide vs Retatrutide: The Complete 2026 Comparison
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated March 2026
Important: We are not doctors. Everything in this article is based on published research and publicly available clinical trial data. It is not medical advice. Talk to your physician before starting or changing any medication.
Key Takeaways
- Semaglutide (Wegovy) targets one receptor, GLP-1. It produced 14.9% average weight loss in the STEP 1 trial. FDA approved. Available now.
- Tirzepatide (Zepbound/Mounjaro) targets two receptors, GLP-1 and GIP. It produced 22.5% average weight loss in SURMOUNT-1. FDA approved. Available now.
- Retatrutide targets three receptors, GLP-1, GIP, and glucagon. Phase 2 data showed 24.2% weight loss. Phase 3 data has reached 28.7%. NOT FDA approved. Not yet available outside clinical trials.
- Each step up in receptor targets produces a meaningful jump in weight loss results.
- For most people today, the practical choice is semaglutide or tirzepatide. Retatrutide represents the next generation, likely available around 2027.
Why This Comparison Matters
The GLP-1 drug class has moved faster than almost any other area of pharmacology in recent memory. Three compounds now define the top tier: semaglutide, tirzepatide, and retatrutide. Each one adds a receptor target. Each one pushes average weight loss higher.
Understanding how they differ, what the data actually shows, and what is and is not available today is genuinely useful for anyone navigating this space. This article breaks it down clearly, without hype and without oversimplifying the science.
We cover each drug individually, then put them head-to-head.
Semaglutide (Wegovy / Ozempic): The Proven Baseline
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It was the drug that brought this entire class into mainstream awareness.
How it works
Semaglutide activates a single receptor: GLP-1. This slows gastric emptying, reduces appetite signals in the brain, stimulates insulin release in response to food, and suppresses glucagon from the pancreas. The net effect is that you eat less and your blood sugar stays more stable.
The clinical data
The STEP 1 trial (PMID 33567185) enrolled 1,961 adults with obesity or overweight with at least one weight-related condition. At 68 weeks on semaglutide 2.4mg:
- Average weight loss: 14.9% of body weight
- Participants losing 5% or more: 86.4%
- Participants losing 10% or more: 69.1%
- Participants losing 15% or more: 50.5%
These were landmark results when they were published. For context, most weight loss drugs before this class produced 5-7% average loss.
Approval and availability
Semaglutide at 2.4mg is FDA approved as Wegovy for chronic weight management. Semaglutide at 1mg is approved as Ozempic for type 2 diabetes. Both are available now through standard prescribing.
Monthly cost for Wegovy runs approximately $1,300 without insurance. Coverage has expanded significantly, but gaps remain depending on plan and diagnosis. Compounded semaglutide has been available through certain pharmacies, though FDA policy on compounding is actively shifting.
Side effects
GI side effects are the primary concern: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). These are typically most intense during dose escalation and improve over time for most patients.
Serious but less common risks include pancreatitis, gallbladder disease, and a boxed warning for medullary thyroid carcinoma based on animal studies. Years of post-market real-world data have continued to confirm and refine this risk profile.
Tirzepatide (Zepbound / Mounjaro): The Step Up
Tirzepatide is a dual agonist developed by Eli Lilly. It added GIP receptor activation to the GLP-1 base, and the results were noticeably better.
How it works
Tirzepatide activates two receptors simultaneously: GLP-1 and GIP. GLP-1 activation works the same as semaglutide. The GIP component appears to amplify the insulin response and may enhance GLP-1 receptor signaling. The combination produces stronger appetite suppression and greater metabolic effects than GLP-1 activation alone.
The clinical data
The SURMOUNT-1 trial (PMID 35658024) enrolled 2,539 adults with obesity or overweight with related conditions. At 72 weeks on tirzepatide 15mg:
- Average weight loss: 22.5% of body weight
- At 10mg: average weight loss of 21.4%
- At 5mg: average weight loss of 16.0%
- 57% of participants on the highest dose achieved at least 20% body weight loss
The jump from semaglutide's 14.9% to tirzepatide's 22.5% is significant. That is roughly 50% more weight lost on average.
For a detailed breakdown of the semaglutide vs tirzepatide comparison, see our dedicated comparison page.
Approval and availability
Tirzepatide is FDA approved as Mounjaro for type 2 diabetes (2022) and as Zepbound for obesity management (2023). Both are available now through standard prescribing.
Monthly cost is comparable to Wegovy, approximately $1,000-$1,300 depending on dose. Insurance coverage patterns are similar to semaglutide.
Side effects
Side effects are similar to semaglutide. GI symptoms dominate: nausea, diarrhea, vomiting, constipation. Rates are dose-dependent. At the highest dose, they are comparable to semaglutide's profile.
Tirzepatide carries the same GLP-1 class warnings regarding pancreatitis, gallbladder disease, and medullary thyroid carcinoma. Post-approval real-world data is building.
Retatrutide: The Triple Agonist
Retatrutide is the next drug from Eli Lilly's pipeline. It adds a third receptor target, glucagon, on top of the GLP-1 and GIP base tirzepatide uses. The results have produced some of the highest weight loss numbers ever recorded in a controlled trial.
How it works
Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The GLP-1 and GIP components work as described above. The glucagon receptor activation is what separates retatrutide from everything that came before it.
Glucagon receptor activation works through different pathways than the appetite-reduction mechanisms of GLP-1 and GIP:
- Direct fat oxidation in adipose tissue and the liver
- Increased hepatic lipid metabolism — glucagon signals the liver to break down stored fat
- Higher resting energy expenditure — metabolic rate increases independent of caloric intake
- Accelerated lipolysis — fat cells release stored fatty acids more readily
In plain terms: GLP-1 and GIP work primarily by reducing how much you eat. Glucagon receptor activation also increases how much fat your body burns. That combination is the theoretical explanation for retatrutide's outsized results.
For the full deep-dive on retatrutide, see our retatrutide overview page.
The clinical data
The Phase 2 trial (PMID 37385275) enrolled adults with obesity without type 2 diabetes. At 48 weeks on the 12mg dose:
- Average weight loss: 24.2% of body weight
- Weight loss curve had not yet plateaued at 48 weeks
- Significant reductions in fat mass across all dose groups
Phase 3 data has continued to impress. Preliminary results from the TRIUMPH program have shown 28.7% body weight loss at the highest dose, with some subgroup data suggesting the weight loss curve continues to decline past 48 weeks.
The TRIUMPH Phase 3 trials are ongoing. Full peer-reviewed Phase 3 data has not yet been published as of this writing.
For more on the trial data, see our retatrutide clinical trials breakdown.
Approval and availability
Retatrutide is NOT FDA approved. It is not available through any legal prescribing channel. It is still in Phase 3 clinical trials. Based on typical FDA review timelines, earliest approval would come around 2027.
Anyone selling "retatrutide" online is selling a research chemical with zero quality guarantees. We do not recommend sourcing unapproved compounds outside of clinical trials. For information on clinical trial access, see our guide on how to get retatrutide.
Side effects
GI side effects follow the same pattern as the rest of this drug class. Retatrutide introduces one additional signal not seen with the other two: dysesthesia, a tingling or numbness sensation reported in approximately 5-9% of Phase 2 participants. This appears linked to glucagon receptor activation and is being monitored in Phase 3 trials.
Preclinical animal studies have identified cancer-related signals in the glucagon receptor pathway. These are animal model findings only and do not establish cancer risk in humans. They are part of the ongoing safety evaluation for the TRIUMPH program.
Head-to-Head: The Full Comparison Table
| Factor | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Retatrutide |
|---|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly | Eli Lilly |
| Receptor targets | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Mechanism type | Single agonist | Dual agonist | Triple agonist |
| Brand name | Wegovy / Ozempic | Zepbound / Mounjaro | None (not approved) |
| FDA approval | Yes (obesity, 2021) | Yes (obesity, 2023) | No |
| Development stage | Market | Market | Phase 3 trials |
| Key trial | STEP 1 (Phase 3) | SURMOUNT-1 (Phase 3) | Phase 2 + TRIUMPH (ongoing) |
| Average weight loss | 14.9% at 68 wks | 22.5% at 72 wks | 24.2% (Ph2) / 28.7% (Ph3 prelim) |
| Trial size (key trial) | 1,961 participants | 2,539 participants | ~338 (Phase 2) |
| Dosing frequency | Weekly injection | Weekly injection | Weekly injection |
| Expected approval | N/A (approved) | N/A (approved) | ~2027 |
| Current monthly cost | ~$1,300 | ~$1,000-1,300 | Not available |
| Insurance coverage | Expanding | Expanding | N/A |
| Common side effects | GI (nausea, diarrhea) | GI (nausea, diarrhea) | GI + dysesthesia |
| Real-world safety data | Years of post-market data | Building post-approval | Phase 3 only |
| Key trial PMID | 33567185 | 35658024 | 37385275 |
Which One Is Best? The Honest Answer
The word "best" depends entirely on your situation. Here is how to think about it.
If you need something available today
Semaglutide and tirzepatide are both available now. Retatrutide is not. This single fact eliminates the comparison for most people who are actively looking to start treatment.
Between semaglutide and tirzepatide, the weight loss data favors tirzepatide. If you have a choice and tolerate both options, tirzepatide's numbers are consistently stronger across all doses.
That said, some people respond better to semaglutide. Prior GLP-1 experience, insurance coverage, tolerance, and prescriber preference all factor in. Neither option is wrong.
If you have not responded well to GLP-1-only drugs
Some people do not get strong results from semaglutide. They lose some weight but plateau earlier or at a lower percentage than average. Adding GIP activation through tirzepatide has helped some of these patients, and adding glucagon activation through retatrutide may help further once it becomes available.
This is a legitimate reason to watch the retatrutide data closely if semaglutide has not worked well for you.
If you are willing to wait for the strongest option
Retatrutide's Phase 3 data, if it holds up, would make it the most effective drug in this class. The 28.7% average weight loss figure, if confirmed in the full peer-reviewed dataset, is in a different category from the approved drugs.
The tradeoff is time (likely 2027 at the earliest) and the fact that long-term safety data does not yet exist at scale.
The realistic view
For most people looking for weight loss support right now, the conversation is between semaglutide and tirzepatide. Retatrutide belongs in the "watch this space" category. The science is genuinely exciting. The drug is not yet available. For a ranked comparison of all three against the full range of available weight loss peptides, see our best peptide for weight loss in 2026 guide.
The Muscle Loss Question Across All Three
A real concern with aggressive pharmacological weight loss is the loss of lean mass alongside fat. Research on GLP-1 medications suggests that a meaningful portion of weight lost can come from muscle, not just fat.
Retatrutide's glucagon component is theoretically relevant here. Glucagon promotes fat oxidation specifically, which may help preserve lean mass during weight loss. Early Phase 2 data suggests a favorable body composition ratio, but this has not been confirmed in large-scale studies.
Tirzepatide and semaglutide have similar lean mass loss patterns in published data. Anyone using any of these drugs should discuss resistance training and protein intake with their care team to mitigate this effect.
This is an open question for all three compounds, and one where retatrutide's glucagon mechanism may eventually show a clinically meaningful advantage.
Related Comparisons
- Retatrutide vs Wegovy: How the next-gen triple agonist stacks up
- Retatrutide vs Tirzepatide: What the research shows
- Retatrutide clinical trials 2026: TRIUMPH program update
- How to get retatrutide: clinical trial access and what to expect
Frequently Asked Questions {#faq}
Is retatrutide better than semaglutide?
In clinical trials, retatrutide produced significantly more weight loss than semaglutide (24-28% vs 14.9%). The mechanism is also more comprehensive, adding glucagon receptor activation on top of the GLP-1 base. However, retatrutide is not FDA approved and is not yet available. Semaglutide has years of real-world safety data that retatrutide does not yet have.
Is tirzepatide stronger than semaglutide?
Yes, based on available trial data. Tirzepatide's SURMOUNT-1 trial showed 22.5% average weight loss at the highest dose versus semaglutide's 14.9% in STEP 1. These trials were not head-to-head, but the gap across multiple datasets is consistent. Both are FDA approved and available now.
What is the difference between a single, dual, and triple agonist?
A single agonist (semaglutide) targets one receptor. A dual agonist (tirzepatide) targets two, GLP-1 and GIP. A triple agonist (retatrutide) targets three, GLP-1, GIP, and glucagon. Each additional receptor adds a different metabolic mechanism. The glucagon component in retatrutide specifically adds direct fat oxidation and increased energy expenditure.
Which GLP-1 drug causes the least side effects?
All three share a similar GI side effect profile: nausea, vomiting, diarrhea, and constipation. These are dose-dependent and typically improve after the initial dose escalation period. Retatrutide introduces an additional signal, dysesthesia (tingling or numbness), not seen with the other two. Semaglutide has the most post-market safety data because it has been on the market the longest.
When will retatrutide be approved?
Eli Lilly is running Phase 3 trials under the TRIUMPH program. Based on current trial timelines and standard FDA review periods, the earliest realistic approval window is around 2027. That timeline could shift depending on trial results, FDA review priorities, and any safety signals that emerge from ongoing studies.
Can I take semaglutide and then switch to tirzepatide or retatrutide?
Switching between GLP-1 class drugs is done under physician supervision. It is not uncommon for patients who plateau on semaglutide to be transitioned to tirzepatide. Retatrutide will not be an option until it receives FDA approval. Any medication transition should be managed by a licensed prescriber.
Is Wegovy the same as Ozempic?
Both contain semaglutide, but they are different products approved for different indications. Wegovy (semaglutide 2.4mg) is approved for chronic weight management. Ozempic (semaglutide 0.5mg, 1mg, 2mg) is approved for type 2 diabetes. The weight management dose in Wegovy is higher.
Medical Disclaimer
This article is produced by the Peptide Nerds editorial team for informational and educational purposes only. We are not physicians, pharmacists, or licensed healthcare providers. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendations.
Retatrutide is an investigational compound. It is not FDA approved for any indication. Tirzepatide is FDA approved under the brand names Mounjaro (type 2 diabetes) and Zepbound (obesity management). Semaglutide is FDA approved under the brand names Ozempic (type 2 diabetes) and Wegovy (chronic weight management). All drugs carry risks and contraindications that are individual to the patient.
Always consult a qualified physician before starting, changing, or stopping any medication, supplement, or health protocol.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID 35658024
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. A Phase 2 Trial. N Engl J Med. 2023. PMID 37385275
Schema Markup
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "Organization",
"@id": "https://peptidenerds.com/#organization",
"name": "Peptide Nerds",
"url": "https://peptidenerds.com",
"logo": {
"@type": "ImageObject",
"url": "https://peptidenerds.com/images/logo.png"
}
},
{
"@type": "Article",
"@id": "https://peptidenerds.com/blog/semaglutide-vs-tirzepatide-vs-retatrutide/#article",
"headline": "Semaglutide vs Tirzepatide vs Retatrutide: The Complete 2026 Comparison",
"description": "Side-by-side comparison of all three GLP-1 drugs: single, dual, and triple agonist. Weight loss data, approval status, side effects, and which one fits your situation.",
"datePublished": "2026-03-14",
"dateModified": "2026-03-14",
"author": {
"@type": "Organization",
"name": "Peptide Nerds Editorial Team"
},
"publisher": {
"@id": "https://peptidenerds.com/#organization"
},
"mainEntityOfPage": {
"@type": "WebPage",
"@id": "https://peptidenerds.com/blog/semaglutide-vs-tirzepatide-vs-retatrutide/"
},
"image": {
"@type": "ImageObject",
"url": "https://peptidenerds.com/images/semaglutide-vs-tirzepatide-vs-retatrutide.jpg"
},
"keywords": "semaglutide vs tirzepatide vs retatrutide, best weight loss peptide 2026, triple agonist, glp-1 comparison, wegovy vs mounjaro vs retatrutide"
},
{
"@type": "FAQPage",
"@id": "https://peptidenerds.com/blog/semaglutide-vs-tirzepatide-vs-retatrutide/#faq",
"mainEntity": [
{
"@type": "Question",
"name": "Is retatrutide better than semaglutide?",
"acceptedAnswer": {
"@type": "Answer",
"text": "In clinical trials, retatrutide produced significantly more weight loss than semaglutide (24-28% vs 14.9%). However, retatrutide is not FDA approved and is not yet available. Semaglutide has years of real-world safety data that retatrutide does not yet have."
}
},
{
"@type": "Question",
"name": "Is tirzepatide stronger than semaglutide?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Yes, based on available trial data. Tirzepatide's SURMOUNT-1 trial showed 22.5% average weight loss at the highest dose versus semaglutide's 14.9% in STEP 1. Both are FDA approved and available now."
}
},
{
"@type": "Question",
"name": "What is the difference between a single, dual, and triple agonist?",
"acceptedAnswer": {
"@type": "Answer",
"text": "A single agonist (semaglutide) targets one receptor, GLP-1. A dual agonist (tirzepatide) targets two: GLP-1 and GIP. A triple agonist (retatrutide) targets three: GLP-1, GIP, and glucagon. Each additional receptor adds a different metabolic mechanism."
}
},
{
"@type": "Question",
"name": "When will retatrutide be approved?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Eli Lilly is running Phase 3 trials under the TRIUMPH program. Based on current trial timelines and standard FDA review periods, the earliest realistic approval window is around 2027."
}
},
{
"@type": "Question",
"name": "Which GLP-1 drug causes the least side effects?",
"acceptedAnswer": {
"@type": "Answer",
"text": "All three share a similar GI side effect profile: nausea, vomiting, diarrhea, and constipation. Retatrutide introduces an additional signal called dysesthesia (tingling or numbness) not seen with the other two. Semaglutide has the most post-market safety data."
}
},
{
"@type": "Question",
"name": "Is Wegovy the same as Ozempic?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Both contain semaglutide, but at different doses for different indications. Wegovy (semaglutide 2.4mg) is approved for chronic weight management. Ozempic (semaglutide up to 2mg) is approved for type 2 diabetes."
}
},
{
"@type": "Question",
"name": "Can I switch from semaglutide to tirzepatide or retatrutide?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Switching between GLP-1 class drugs is done under physician supervision. Transitioning from semaglutide to tirzepatide is not uncommon for patients who plateau. Retatrutide will not be an option until it receives FDA approval."
}
}
]
}
]
}
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.